Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Archer

Showing results (131-140 of 175) with videos related to

Pageof 18
Sort By:
Contraception|August 25, 2004
A phase I comparative postcoital testing study of three concentrations of C31GChristine K Mauck, Mitchell D Creinin, Kurt T Barnhart, et al.
Obstetrics and Gynecology|June 12, 2018
A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled TrialRogerio A Lobo, David F Archer, Risa Kagan, et al.
Contraception|April 26, 2024
Use of serum evaluation of contraceptive and ovarian hormones to assess reduced risk of pregnancy among women presenting for emergency contraception in a multicenter clinical trialJeffrey T Jensen, Alison Edelman, Carolyn L Westhoff, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|December 5, 2015
Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicatorMarlene Montesino, Fernand Labrie, David F Archer, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 15, 2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeksCéline Martel, Fernand Labrie, David F Archer, et al.
Menopause (New York, N.Y.)|March 4, 2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone)David F Archer, Fernand Labrie, Céline Bouchard, et al.
Contraception|April 25, 2024
Emergency contraception for individuals weighing 80 kg or greater: A randomized trial of 30 mg ulipristal acetate and 1.5 mg or 3.0 mg levonorgestrelAlison Edelman, Jeffrey T Jensen, Jill Brown, et al.
Fertility and Sterility|June 6, 2007
Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal womenDavid F Archer, Susan Hendrix, Alex Ferenczy, et al.
Menopause (New York, N.Y.)|January 30, 2019
Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trialDavid F Archer, Steven R Goldstein, James A Simon, et al.
Contraception|May 17, 2021
Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety resultsMitchell D Creinin, Carolyn L Westhoff, Céline Bouchard, et al.
Pageof 18

Showing results (131-140 of 175) with videos related to

Sort By:
Pageof 18
Contraception|August 25, 2004
A phase I comparative postcoital testing study of three concentrations of C31GChristine K Mauck, Mitchell D Creinin, Kurt T Barnhart, et al.
Obstetrics and Gynecology|June 12, 2018
A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled TrialRogerio A Lobo, David F Archer, Risa Kagan, et al.
Contraception|April 26, 2024
Use of serum evaluation of contraceptive and ovarian hormones to assess reduced risk of pregnancy among women presenting for emergency contraception in a multicenter clinical trialJeffrey T Jensen, Alison Edelman, Carolyn L Westhoff, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|December 5, 2015
Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicatorMarlene Montesino, Fernand Labrie, David F Archer, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 15, 2016
Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeksCéline Martel, Fernand Labrie, David F Archer, et al.
Menopause (New York, N.Y.)|March 4, 2015
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone)David F Archer, Fernand Labrie, Céline Bouchard, et al.
Contraception|April 25, 2024
Emergency contraception for individuals weighing 80 kg or greater: A randomized trial of 30 mg ulipristal acetate and 1.5 mg or 3.0 mg levonorgestrelAlison Edelman, Jeffrey T Jensen, Jill Brown, et al.
Fertility and Sterility|June 6, 2007
Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal womenDavid F Archer, Susan Hendrix, Alex Ferenczy, et al.
Menopause (New York, N.Y.)|January 30, 2019
Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trialDavid F Archer, Steven R Goldstein, James A Simon, et al.
Contraception|May 17, 2021
Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety resultsMitchell D Creinin, Carolyn L Westhoff, Céline Bouchard, et al.
Pageof 18